Tools
Stock profile

InfuSystem Holdings, Inc (INFU)

INFU · Latest close $14.67 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$14.67
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
1
vs previous quarter

InfuSystem Holdings, Inc (INFU) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund trimming or exiting versus the previous quarter. Latest close $14.67 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

First Eagle Investment Management — 1 tracked fund hold INFU. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
First Eagle Investment Management0.01%620,000TRIMMED (-14.1%) Q3 filed Nov 10

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +47.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

15.284.282024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding98 of 8,857 filers
Long-only filers among them98
Change vs 2026 Q1+7 net · 97 entered · 90 exited
Shares reported, all filers15,022,929
Reported value, all filers$136.1M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustrySurgical & Medical Instruments & Apparatus (SIC 3841)
Revenue · FY2025$143.4M
Net income · FY2025$6.6M
Total assets · FY2025$100.6M
Shares outstanding19,917,181
Market cap (at latest close)$292.2M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 2026813,399
Share of shares outstanding4.08%
Days to cover7.63

Shares short at recent settlements — Jul 31, 2026: 781K · Aug 14, 2026: 734K · Aug 31, 2026: 755K · Sep 15, 2026: 812K · Sep 30, 2026: 864K · Oct 15, 2026: 813K.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 22, 2025Shuda ScottDirector5,752$56.5KAug 22, 2025SEC filing
May 21, 2025Richard DilorioDirector, Officer20,000$122.0KMay 21, 2025SEC filing
Nov 25, 2024Richard DilorioDirector, Officer40,000$373.2KNov 25, 2024SEC filing
Jun 16, 2023Lehman Gregg OwenOfficer25,000$227.7KJun 16, 2023SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Jan 22, 2025SCHEDULE 13D/A+83.3% (close Jan 23, 2025 → Nov 17, 2026)

Reference close is the first trading day after the filing (Jan 23, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Jul 28, 2026BlackRock, Inc.SC 13G1,286,1296.4%Jun 30, 2026SEC filing
Feb 17, 2026Minerva Advisors LLCSC 13G/A1,078,7315.3%Dec 31, 2025SEC filing
Dec 3, 2025Minerva Advisors LLCSC 13G1,025,7985.0%Oct 31, 2025SEC filing
Nov 13, 2025AWM Investment Company, Inc.SC 13G/A561,6562.8%Sep 30, 2025SEC filing
Aug 14, 2025AWM Investment Company, Inc.SC 13G/A1,272,2966.1%Jun 30, 2025SEC filing
Jul 29, 2025The Vanguard GroupSC 13G/A957,6384.6%Jun 30, 2025SEC filing
Jul 17, 2025BlackRock, Inc.SC 13G/A402,4481.9%Jun 30, 2025SEC filing
May 9, 2025AWM Investment Company, Inc.SC 13G/A1,626,2807.7%Mar 31, 2025SEC filing
Jan 22, 2025Sansone Advisors, LLCSC 13D/A939,2944.4%Jan 21, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 28 Lobbying Disclosure Act filings named this company as client, 2015–2022; most common issues: Medicare/Medicaid (26), Health Issues (5).

Federal contracts: $225.2K in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$0
FY2022$0
FY2023$0
FY2024$65.7K
FY2025$113.9K
FY2026$45.6K

Largest awards collected

Award IDAgencyAmountStart
36C26022P0559Department of Veterans Affairs$100.9KMay 1, 2022
36C24123P0403Department of Veterans Affairs$100.7KMar 6, 2023
75N90018P00870Department of Health and Human Services$71.9KSep 25, 2018
HHSN269201800136PDepartment of Health and Human Services$70.0KDec 14, 2017
36C24725P0047Department of Veterans Affairs$69.4KNov 1, 2024

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Piotroski — Financial health improved over the past year

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Shareholder Yield — Cash returned through dividends and buybacks

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Red Flags

· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)

Key figures

· Growth — Latest revenue: $143.4M · 5-yr revenue CAGR: 8.1% · Straight growth years: 7

· Graham — Current ratio: 1.80 · Straight profitable years: 7 · Debt ratio: 0.75 · Latest net income: $6.6M

· Piotroski — F-score: 8 · Return on assets: 6.6% · Operating cash flow: $24.4M

· Cash Flow (FCF) — Latest FCF: $23.8M · FCF yield: 7.8% · Positive FCF years: 3

· Gross Profitability (Novy-Marx) — Gross profit / assets: 79.8% · Gross margin: 56.0%

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 8.43 · Operating cash flow: $24.4M · Net income: $6.6M

· Shareholder Yield — Shareholder yield: 3.2% · of which dividends: 0.0% · of which buybacks: 3.2%

· Auditor Change (8-K 4.01) — Latest event: Mar 19, 2026 · Events in 2 yrs: 1

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 3 of the last 20 quarterly lists; latest 2025 Q2, ranked #29 of 50.

Also held by the tracked funds that hold INFU — ranked by lift, the co-holding pattern described in Methodology: BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) · Medline Inc. (MDLN) · 3M CO (MMM) · WEST PHARMACEUTICAL SERVICES INC (WST).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 9, 20267.01 Regulation FD DisclosureSEC filing
Nov 5, 20262.02 Results of Operations and Financial ConditionSEC filing
Nov 3, 20267.01 Regulation FD DisclosureSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

BECTON DICKINSON & CO (BDX) · Track Record: how the signals scored · Practice timing on INFU

One email a week: the week’s new filings and research. Subscribe free

← INFQ  ·  INFY →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.